Danish govt rolls out the ‘red carpet’ for pharma production companies

4 November 2024

The Danish government is rolling out the red carpet and welcomes several pharmaceutical companies.

It shows how important the industry is to the Danish economy - and can be for Norway if the government follows the Danes' example, says Leif Rune Skymoen, chief executive of Lif - the Pharmaceutical Industry Association in Denmark.

With new measures, the Danish government will make it easier to establish production facilities in Denmark. A total of 102.4 million Danish kroner ($14.9 million) is set aside for red carpets for production companies in the period 2024-2027. The measures are linked to the upcoming Danish Life science strategy.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK